ST Innovative Diagnostics
Monitoring Malignancies trough a Simple Blood Test
Company Overview
Snapshot
Founded in July 2022 by Esther Rabizadeh, ST Innovative Diagnostics operates with 1–10 employees. The company has raised $70,000 across one funding round. In May 2024, the company published research on the presence and activity of Fibrinogen like protein 2 in platelets, a key component of its diagnostic technology.
Business overview
ST Innovative Diagnostics develops a novel blood-based malignancy monitoring test. Its proprietary technology and kit measure Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across various malignancies. The company serves the Health Tech & Life Sciences sector, with a focus on cancer diagnostics, medical devices, and early detection, and plans to expand into solid tumor monitoring and diagnosis.
Strategic signal
In May 2024, ST Innovative Diagnostics published research in journals.plos.org detailing the presence and activity of Fibrinogen like protein 2 in platelets. This publication provides scientific validation for the core mechanism of the company's blood-based malignancy monitoring test, reinforcing the credibility of its diagnostic approach and potentially accelerating clinical adoption and investor confidence in its technology.
Company Intelligence Q&A
- What is ST Innovative Diagnostics' core technology?
- ST Innovative Diagnostics has developed a novel blood-based malignancy monitoring test that measures Fibrinogen Like Protein 2 (FGL2) activity in platelets. This technology enables non-invasive disease monitoring and relapse prediction across multiple malignancies.
- When was ST Innovative Diagnostics founded?
- ST Innovative Diagnostics was founded in July 2022.
- What is the primary focus of ST Innovative Diagnostics' product development?
- The company's primary focus is on non-invasive disease monitoring and relapse prediction for various malignancies, with initial clinical studies showing correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma.
- What was a significant recent scientific publication by ST Innovative Diagnostics?
- In May 2024, ST Innovative Diagnostics published research on journals.plos.org concerning the presence and activity of Fibrinogen like protein 2 in platelets, which is integral to their diagnostic method.
- What markets does ST Innovative Diagnostics aim to serve?
- ST Innovative Diagnostics aims to serve the global market, with plans to expand its technology for solid tumor monitoring and diagnosis, including Metastatic Colorectal and Pancreatic Cancers.